Aardvark Therapeutics

AARD

Börsenwert 82,7 Mio. $

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv-04643, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the “IPO” or “Offering”); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”).  Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.

New York, New York--(Newsfile Corp. - October 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events" and "no renal or hepatic safety limitations" — language the complaint contends did not disclose the specific cardiac safety issues that later drew a full FDA clinical hold. A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events" and "no renal or hepatic safety limitations" — language the complaint contends did not disclose the specific cardiac safety issues that later drew a full FDA clinical hold.

New class action for Aardvark (AARD) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/13/2026

NEW YORK--(BUSINESS WIRE)---- $AARD #AARD--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi.

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline. So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD New York, New York--(Newsfile Corp. - October 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 12, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

SAN FRANCISCO, Oct. 12, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.

NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 13, 2025 and May 14, 2026.  Request an institutional investor loss assessment.